JP2019507793A5 - - Google Patents

Download PDF

Info

Publication number
JP2019507793A5
JP2019507793A5 JP2018547964A JP2018547964A JP2019507793A5 JP 2019507793 A5 JP2019507793 A5 JP 2019507793A5 JP 2018547964 A JP2018547964 A JP 2018547964A JP 2018547964 A JP2018547964 A JP 2018547964A JP 2019507793 A5 JP2019507793 A5 JP 2019507793A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
compound according
heteroaryl
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018547964A
Other languages
English (en)
Japanese (ja)
Other versions
JP6972002B2 (ja
JP2019507793A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/021966 external-priority patent/WO2017156495A1/en
Publication of JP2019507793A publication Critical patent/JP2019507793A/ja
Publication of JP2019507793A5 publication Critical patent/JP2019507793A5/ja
Application granted granted Critical
Publication of JP6972002B2 publication Critical patent/JP6972002B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018547964A 2016-03-11 2017-03-10 ブルトン型チロシンキナーゼを調節する化合物及び方法 Active JP6972002B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662307399P 2016-03-11 2016-03-11
US62/307,399 2016-03-11
US201662342004P 2016-05-26 2016-05-26
US62/342,004 2016-05-26
PCT/US2017/021966 WO2017156495A1 (en) 2016-03-11 2017-03-10 Compounds and methods for modulating bruton's tyrosine kinase

Publications (3)

Publication Number Publication Date
JP2019507793A JP2019507793A (ja) 2019-03-22
JP2019507793A5 true JP2019507793A5 (https=) 2020-05-14
JP6972002B2 JP6972002B2 (ja) 2021-11-24

Family

ID=59789888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018547964A Active JP6972002B2 (ja) 2016-03-11 2017-03-10 ブルトン型チロシンキナーゼを調節する化合物及び方法

Country Status (12)

Country Link
US (2) US10870652B2 (https=)
EP (1) EP3426637B1 (https=)
JP (1) JP6972002B2 (https=)
KR (1) KR102416971B1 (https=)
CN (2) CN109071455B (https=)
AU (1) AU2017230098B2 (https=)
ES (1) ES2912465T3 (https=)
IL (1) IL261583A (https=)
MX (1) MX388026B (https=)
PL (1) PL3426637T3 (https=)
WO (1) WO2017156495A1 (https=)
ZA (1) ZA201805951B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071455B (zh) * 2016-03-11 2022-08-02 嘉兴和剂药业有限公司 用于调节布鲁顿酪氨酸激酶的化合物及方法
JOP20190113A1 (ar) * 2016-11-18 2019-05-15 Biocad Joint Stock Co مثبطات بروتون تيروزين كيناز
WO2018175512A1 (en) * 2017-03-22 2018-09-27 Suzhou Baijibugong Pharmaceutical Technology Co. Ltd. Bruton's tyrosine kinase inhibitors
KR102384924B1 (ko) * 2017-07-12 2022-04-08 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
CN108191871B (zh) * 2018-01-02 2020-02-18 成都倍特药业有限公司 新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用
CN111662232B (zh) * 2019-03-06 2022-08-02 中国科学院上海药物研究所 具有2h-吲唑结构的小分子化合物及其合成和应用
CN113544130B (zh) 2019-05-31 2024-01-09 西藏海思科制药有限公司 一种btk抑制剂环衍生物及其制备方法和药学上的应用
WO2020252397A1 (en) * 2019-06-12 2020-12-17 Baylor College Of Medicine Small molecule proteolysis-targeting chimeras and methods of use thereof
FI4036095T3 (fi) * 2019-09-26 2024-02-14 Jumbo Drug Bank Co Ltd 4-Fluori-1H-pyratsolo[3,4-c]pyridiinijohdannaisia selektiivisinä Brutonin tyrosiinikinaasin (BTK) inhibiittoreina B-solulymfooman ja autoimmuunitautien hoitamiseksi
CN114437078A (zh) * 2020-11-03 2022-05-06 海思科医药集团股份有限公司 一种降解btk的氘代物及其在医药上的应用
CN117377675A (zh) * 2021-06-01 2024-01-09 正大天晴药业集团股份有限公司 含有并环或螺环的布鲁顿酪氨酸激酶降解剂
TW202321191A (zh) * 2021-07-29 2023-06-01 美商賽迪拉治療股份有限公司 Tead抑制劑及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW502019B (en) * 1999-03-26 2002-09-11 Cocensys Inc Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
SE0301906D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
KR101417136B1 (ko) * 2005-12-13 2014-08-07 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 폴리사이클릭 인다졸 유도체 및 이를 포함하는 약제학적 조성물
WO2007095223A2 (en) * 2006-02-14 2007-08-23 Vertex Pharmaceuticals Incorporated Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
US20120101114A1 (en) * 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
ES2396613T3 (es) * 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
CA2730930C (en) * 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US8633318B2 (en) 2008-09-16 2014-01-21 Proximagen Ltd Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
KR101301533B1 (ko) 2010-02-09 2013-09-04 한미사이언스 주식회사 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체
JP2014520863A (ja) * 2011-07-13 2014-08-25 ファーマサイクリックス,インク. Bruton型チロシンキナーゼの阻害剤
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CN104080789B (zh) 2012-01-31 2016-05-11 南京奥昭生物科技有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
WO2014022569A1 (en) 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
JP2016538270A (ja) 2013-10-25 2016-12-08 ファーマサイクリックス エルエルシー 移植片対宿主病を処置し予防する方法
WO2015124570A1 (en) 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of influenza a virus infection
EP3414234B1 (en) * 2015-10-14 2022-06-29 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
KR102699906B1 (ko) * 2016-01-21 2024-08-29 즈보 바이오폴라 창쉥 파마수티컬 컴퍼니 리미티드 브루톤 티로신 키나제 억제제
CN109071455B (zh) * 2016-03-11 2022-08-02 嘉兴和剂药业有限公司 用于调节布鲁顿酪氨酸激酶的化合物及方法

Similar Documents

Publication Publication Date Title
JP2019507793A5 (https=)
JP2020517600A5 (https=)
EP3209656B1 (en) Indole carboxamides compounds useful as kinase inhibitors
CN115734966A (zh) 杂环化合物及其用途
JP2022536755A5 (https=)
JP2024529347A5 (https=)
JP2019514883A5 (https=)
US9714234B2 (en) Carbazole carboxamide compounds
JP2018505898A5 (https=)
JP2012507522A5 (https=)
JP2011509309A5 (https=)
JP2020505395A5 (https=)
RU2004111979A (ru) Производные 1н-имидазола, обладающие св1-агонистической, частичной св1-агонистической или св1-антагонистической активностью
JP2019510787A5 (https=)
JP2020534373A5 (https=)
JP2008516945A5 (https=)
JP2018519357A5 (https=)
JP2017528498A5 (https=)
CA2446756A1 (en) Thiazole compounds useful as inhibitors of protein kinase
JP2021502387A5 (https=)
JP6672296B2 (ja) 強力なγ−セクレターゼモジュレータ
JP2009539848A5 (https=)
US10023534B2 (en) Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK
JP2017519754A5 (https=)
JP2025503448A5 (https=)